尤瑞克林联合依达拉奉治疗进展性脑梗死44例临床研究

Clinical research of Kailldinogenase combined Edarovone treating progressive cerebral infarction 44 cases report

目的探讨尤瑞克林联合依达拉奉治疗进展性脑梗死的临床疗效及作用机制。方法选择收治的进展性脑梗死患者132例随机分为3组,每组44例,3组均予改善循环、抗血小板聚集等常规治疗。C组在常规治疗基础上予胞二磷胆碱+血栓通静滴,波立维口服;B组在C组基础上予依达拉奉静滴;A组在B组基础上加尤瑞克林静滴。均14天为1疗程。并于治疗前后进行临床神经功能缺损程度(CSS)评分与日常生活活动能力量表(BI)评分,观察3组临床疗效,并监测不良反应。结果 A组神经功能缺损的治疗效果及控制脑梗死进展优于B、C组,且无明显不良反应。结论尤瑞克林联合依达拉奉对进展性脑梗死具有较好的治疗效果。

Objective To research the clinical efficacy and the possible function mechanism of Kailldinogenase combined Edarovone treating progressive cerebral infarction. Methods 132 cases with progressive cerebral infarction were randomized into three groups. Each group included 44 cases. All the patients received routine treatment for improving circulation and anti-platelet aggregation. In addition,group C received citieoline＋sanqi panax notoginseng （i. v. ） and oral Plavix. Group B received additional edarovone （i. v. ） based on the regime of group C and group A received additional Kailldinogenase based on the regime of group B with 14 days as a period. The clinical neurologic deficit scale （CSS） and barthel index （BI） were assessed before and after treatment. The clinical efficacy was observed and the side effects were monitored. Results The clinical efficacy and control of the progress of the cerebral infarction in the treatment group were better than those in the control groups. There was no side effect. Conclusion Kailldinogenase co-mbined Edarovone shows good clinical efficacy in treating progressive cerebral infarction.